Sarepta's Duchenne gene therapy misses main goal in late-stage study; shares fall – Reuters

Written by

admin

in

  1. Sarepta’s Duchenne gene therapy misses main goal in late-stage study; shares fall  Reuters
  2. Sarepta’s Duchenne gene therapy misses main goal in study  MarketScreener
  3. Sarepta Therapeutics: Q3 Earnings Snapshot  News-Times
  4. Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint  StreetInsider
  5. Sarepta stock plunges after ESSENCE trial misses primary endpoint  Investing.com

Continue Reading

More posts